Parsons, C.M.
,
Harvey, N.
Shepstone, L.
Kanis, J.A.
Lenaghan, E.
Clarke, S.
Fordham, R.
Gittoes, N.
Harvey, I.
Holland, R.
Redmond, N.M.
Howe, A.
Marshall, T.
Peters, T.J.
Torgerson, D.
O’Neill, T.W.
McCloskey, E.
Cooper, C. http://orcid.org/0000-0003-3510-0709
Article History
Received: 16 April 2019
Accepted: 20 August 2019
First Online: 12 October 2019
Compliance with ethical standards
:
: CC has received consultancy fees and honoraria from Amgen, Danone, Eli Lilly, GlaxoSmithKline, Medtronic, Merck, Nestlé, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB. NH has received consultancy, lecture fees and honoraria from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Servier, Shire, UCB, Consilient Healthcare and Internis Pharma. JK has held grants from Amgen, Lilly, Unigene and Radius Health; has received non-financial support from Medimaps, Asahi and AgNovos; and is the architect of FRAX<sup>®</sup>, but has no financial interest. EM has been, or currently is, an adviser or speaker for and has received research support from ActiveSignal, Amgen, AstraZeneca, Consilient Healthcare, GlaxoSmithKline, Hologic, Internis, Eli Lilly, Medtronic, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Synexus, Tethys, UCB and Warner Chilcott; and has received research support from I3 Innovus, International Osteoporosis Foundation and Unilever. All other authors declare no competing interests.